HAMBURG — Clinical trials on ocriplasmin, including subgroup analysis of best responders, have shown patient selection plays a crucial role in the success of the therapy and may account for discrepancies in response rate from site to site, according to a speaker here.“Ocriplasmin is not the same as other intravitreal injections we are currently utilizing in clinical practice. Who and how we inject may be important,” Baruch Kuppermann, MD, said at the Euretina meeting.
EYLEA® meets primary endpoint in two Phase III trials for the treatment of diabetic macular oedema
Bayer HealthCare has announced that EYLEA (aflibercept solution for injection, known in the scientific literature as VEGF Trap-Eye) has achieved the primary endpoint in two pivotal phase III trials for the treatment of diabetic macular oedema (DMO),1 t…
Observe and Plan Strategy Touted for Macular Degeneration
Individualized long-term treatment plans can lead to fewer injections for patients with age-related macular degeneration. Medscape Medical News
INTREPID Trial: Radiotherapy Safe for Macular Degeneration
No safety signals emerged at 2 years with radiotherapy for neovascular age-related macular degeneration. Monitoring for microvascular changes is ongoing. Medscape Medical News
13th EURETINA Congress
Read clinically focused news coverage of key developments from EURETINA 2013. Medscape Ophthalmology
Glaucoma Surgery by Surgeons
The American Glaucoma Society takes the position that all surgery for glaucoma, including lasers, should only be performed by surgeons with subspecialty training. Journal of Glaucoma